Literature DB >> 12466783

Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation.

Felix Y j Keng1, Su Min Chang, Eduardo Cwajg, Zuo-Xiang He, Nasser M Lakkis, Sherif F Nagueh, William H Spencer, Mario S Verani.   

Abstract

BACKGROUND: Transcoronary ethanol septal ablation (TESA) is a novel treatment for obstructive hypertrophic cardiomyopathy (HOCM). Our objective was to evaluate the use of gated single photon emission computed tomography (SPECT) in patients with HOCM and the effects of TESA on myocardial perfusion. METHODS AND
RESULTS: We performed gated SPECT and Doppler echocardiography before and 6 weeks after TESA in 30 patients with severe HOCM. The lung-to-heart and septal-to-lateral wall count-activity ratios were calculated. Before ablation, SPECT showed perfusion abnormalities in only 6 patients. Asymmetric septal hypertrophy was noted in 21 patients (70%). In patients with a lung-to-heart ratio greater than 0.50 before ablation, the ratio decreased from 0.56 +/- 0.04 to 0.45 +/- 0.08 after ablation (P <.01). The septal-to-lateral wall ratio also decreased significantly after ablation. Mean Doppler pressure gradient across the left ventricular outflow tract decreased from 52 +/- 39 mm Hg to 13 +/- 13 mm Hg (P <.01) immediately after ablation and to 10 +/- 21 mm Hg 6 weeks later (P <.01). There were no significant changes in left ventricular ejection fraction by gated SPECT after the procedure. SPECT studies done after ablation showed fixed septal defects in 29 of 30 patients (96.7%). The defects involved the basal and mid septum in 100% and 38% of patients, respectively, and ranged in size from 2% to 30% of the left ventricle (mean, 8.8% +/- 7.0%).
CONCLUSIONS: TESA is an effective technique for relieving left ventricular outflow obstruction in patients with HOCM. Myocardial gated SPECT can identify the presence and location of infarction after TESA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466783     DOI: 10.1067/mnc.2002.125997

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  31 in total

1.  Septal coronary artery ablation for hypertrophic obstructive cardiomyopathy.

Authors:  V K Bahl; S Chandra; A K Chopra
Journal:  Indian Heart J       Date:  1996 Nov-Dec

2.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.

Authors:  H Seggewiss; U Gleichmann; L Faber; D Fassbender; H K Schmidt; S Strick
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

3.  Gated myocardial perfusion tomography for the assessment of left ventricular function and volumes: comparison with echocardiography.

Authors:  E Cwajg; J Cwajg; Z X He; W S Hwang; F Keng; S F Nagueh; M S Verani
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

4.  Postexercise lung uptake of 99mTc-sestamibi determined by a new automatic technique: validation and application in detection of severe and extensive coronary artery disease and reduced left ventricular function.

Authors:  C Bacher-Stier; T Sharir; P B Kavanagh; H C Lewin; J D Friedman; R Miranda; G Germano; D S Berman
Journal:  J Nucl Med       Date:  2000-07       Impact factor: 10.057

5.  Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy.

Authors:  R O Cannon; V Dilsizian; P T O'Gara; J E Udelson; W H Schenke; A Quyyumi; L Fananapazir; R O Bonow
Journal:  Circulation       Date:  1991-05       Impact factor: 29.690

6.  [Hemodynamic significance of diffuse lung uptake of 201Tl in heart diseases].

Authors:  T Fujii; H Kanai; M Tanaka; Y Hirose; O Kinoshita; J Kono; J Hirayama; M Hongo; H Yamada; S Okubo
Journal:  Kaku Igaku       Date:  1989-05

7.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

Authors:  U Sigwart
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

8.  Recognition of regional hypertrophy in hypertrophic cardiomyopathy using thallium-201 emission-computed tomography: comparison with two-dimensional echocardiography.

Authors:  Y Suzuki; K Kadota; R Nohara; S Tamaki; H Kambara; A Yoshida; T Murakami; G Osakada; C Kawai; N Tamaki
Journal:  Am J Cardiol       Date:  1984-04-01       Impact factor: 2.778

9.  Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography.

Authors:  P T O'Gara; R O Bonow; B J Maron; B A Damske; A Van Lingen; S L Bacharach; S M Larson; S E Epstein
Journal:  Circulation       Date:  1987-12       Impact factor: 29.690

10.  Significance of increased lung thallium uptake during adenosine thallium-201 scintigraphy.

Authors:  S Nishimura; J J Mahmarian; M S Verani
Journal:  J Nucl Med       Date:  1992-09       Impact factor: 10.057

View more
  3 in total

Review 1.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

2.  Fifth Annual Mario S. Verani, MD Memorial Lecture: evolving challenges and opportunities.

Authors:  Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

3.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.

Authors:  Horst Kuhn; Thorsten Lawrenz; Frank Lieder; Christian Leuner; Claudia Strunk-Mueller; Ludger Obergassel; Markus Bartelsmeier; Christoph Stellbrink
Journal:  Clin Res Cardiol       Date:  2007-12-10       Impact factor: 5.460

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.